Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, May 31, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the launch of a new global website. In accordance with the company Disclosure...
Read more about Astellas Announces New Global Website Launch
Tokyo, May 23, 2017 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) on International Day to End Obstetric Fistula, Astellas pledges its support to the Fistula...
Read more about ACTION ON FISTULA TO TRANSFORM 4,500 LIVES BY 2020
Tokyo, May 19, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that MSD has submitted an...
TOKYO – May 17, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today an update regarding the Company’s diverse oncology portfolio,...
Read more about Astellas Announces Oncology Portfolio Updates
Tokyo, May 17, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has completed the acquisition of Ogeda SA (formerly named...
Tokyo, May 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the discontinuation of ASP8273 treatment arm in the the late-stage...
Tokyo, May 11, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...
Tokyo, April 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that Astellas and LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka,...
Tokyo, March 22, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS®...
CAMBRIDGE, Mass. and TOKYO, February 28, 2017 -- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive worldwide license agreement...
Kyowa Pharmaceutical Industry Co., Ltd. (Head office: Yodogawa-ku, Osaka City, President and Representative Director: Ray Tsunoda, hereinafter called “Kyowa”) and Astellas Pharma Inc....
Tokyo, February 23, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that Astellas, Takeda Pharmaceutical Company Limited (President and CEO:...
Tokyo, January 31, 2017 – Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka) today announced that it executed a license agreement with respect to an...
Follow us
